Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 67
Filtrar
2.
Clin Dermatol ; 41(4): 476-480, 2023.
Artículo en Inglés | MEDLINE | ID: mdl-37574152

RESUMEN

Eyelid dermatitis may present with a variety of clinical findings including erythema, pruritus, and edema, and it has a wide differential. Allergic contact dermatitis due to allergen sources in personal care products, cosmetics, and fragrances is a leading cause of eyelid dermatitis and may be challenging to diagnose by clinical examination alone. Expanded patch testing, in addition to careful inspection of the surrounding skin for additional areas of involvement and clinical clues, remains an important tool in differentiating allergic contact dermatitis from other relevant etiologies of eyelid dermatitis including irritant contact dermatitis, atopic dermatitis, seborrheic dermatitis, and rosacea. We present a practical approach to the management of eyelid dermatitis including the use of a topical anti-inflammatory for long-term control of eyelid findings. Further diagnostic workup may be warranted in patients with refractory eyelid dermatitis.


Asunto(s)
Blefaritis , Cosméticos , Dermatitis Alérgica por Contacto , Dermatitis Atópica , Humanos , Dermatitis Alérgica por Contacto/diagnóstico , Dermatitis Alérgica por Contacto/etiología , Dermatitis Atópica/diagnóstico , Párpados , Alérgenos/efectos adversos , Cosméticos/efectos adversos , Pruebas del Parche/efectos adversos , Blefaritis/diagnóstico , Blefaritis/etiología , Blefaritis/terapia
7.
Am J Clin Dermatol ; 23(1): 61-67, 2022 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-34855151

RESUMEN

Dupilumab facial redness (DFR), or the development of an eczematous rash of the face and neck with dupilumab use, has been observed in recent case reports. It is estimated to impact between 4 and 43.8% of dupilumab users, including children and adults. Aside from reviewing the pathogenesis and clinical presentation, we present potential diagnostic steps (such as skin scraping, serologies, biopsy, and patch testing) and management options for DFR ranging from allergen avoidance to dupilumab interruption. It is hoped that this article will serve as a means for clinicians to familiarize themselves with DFR regarding the differential diagnosis, diagnostic tools, and treatment options associated with this phenomenon.


Asunto(s)
Anticuerpos Monoclonales Humanizados/efectos adversos , Eritema/inducido químicamente , Dermatosis Facial/inducido químicamente , Administración Tópica , Antibacterianos/uso terapéutico , Antifúngicos/uso terapéutico , Inhibidores de la Calcineurina/uso terapéutico , Diagnóstico Diferencial , Erupciones por Medicamentos/diagnóstico , Eritema/terapia , Dermatosis Facial/terapia , Glucocorticoides/uso terapéutico , Humanos , Pruebas Cutáneas
8.
Arch Dermatol Res ; 314(8): 805-808, 2022 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-33772628

RESUMEN

Statins have been associated with an increased risk of keratinocyte carcinoma but data are limited and conflicting. Statins are hypothesized to contribute to KC through immunomodulation. A whole-population case-control study of the Icelandic population was conducted using the Icelandic Cancer Registry and Icelandic Prescription Medicine Register. These are high-quality registers which include all cancer diagnoses, as well as every prescription in the country. Cases included all first-time histologically confirmed diagnoses of (BCC), in situ squamous cell carcinoma (SCCis) and invasive SCC between 2003 and 2017. Each case was paired with 10 age- and sex-matched controls. Multivariate conditional logistic regression analysis was performed. Four thousand seven hundred patients with BCC, 1167 patients with SCCis and 1013 patients with invasive SCC were identified and paired with 47,292, 11,961 and 10,367 controls, respectively. Overall statin use was associated with an increased risk of invasive SCC and SCCis but not BCC (adjusted OR [95% CI]: 1.29 [1.11-1.50]; 1.43 [1.24-1.64]; 1.03 [0.95-1.12], respectively). Subgroup analysis demonstrated that statins were significantly associated with invasive SCC and SCCis in patients over 60, but not in those under 60. Atorvastatin was only associated with an increased risk of SCCis; whereas, simvastatin was associated with an increased risk of both invasive SCC and SCCis. This whole-population study of Iceland demonstrates that statin exposure is associated with increased risk of SCC, but not BCC, in a low UV environment. The reasons are unclear, but our results may suggest that individuals receiving atorvastatin and simvastatin have differing levels of baseline keratinocyte cancer risk or that properties of a statin other than 'statin intensity' affect association with SCC.


Asunto(s)
Carcinoma Basocelular , Carcinoma de Células Escamosas , Inhibidores de Hidroximetilglutaril-CoA Reductasas , Neoplasias Cutáneas , Atorvastatina , Carcinoma Basocelular/patología , Carcinoma de Células Escamosas/epidemiología , Carcinoma de Células Escamosas/patología , Estudios de Casos y Controles , Humanos , Inhibidores de Hidroximetilglutaril-CoA Reductasas/efectos adversos , Islandia/epidemiología , Simvastatina , Neoplasias Cutáneas/inducido químicamente , Neoplasias Cutáneas/epidemiología , Neoplasias Cutáneas/patología
10.
J Am Acad Dermatol ; 86(3): 515-524, 2022 03.
Artículo en Inglés | MEDLINE | ID: mdl-34915056

RESUMEN

Despite advances in early detection as described in part 1 of this continuing medical education series, melanoma continues to be a large contributor to cutaneous cancer-related mortality. In a subset of patients with unresectable or metastatic disease, surgical clearance is often not possible; therefore, systemic and local therapies are considered. The second article in this series provides dermatologists with an up-to-date working knowledge of the treatment options that may be prescribed by oncologists for patients with unresectable stage III, stage IV, and recurrent melanoma.


Asunto(s)
Melanoma/terapia , Recurrencia Local de Neoplasia/terapia , Neoplasias Cutáneas/terapia , Educación Médica Continua , Humanos , Inmunoterapia , Melanoma/patología , Recurrencia Local de Neoplasia/patología , Neoplasias Cutáneas/patología
11.
J Am Acad Dermatol ; 86(3): 503-512, 2022 03.
Artículo en Inglés | MEDLINE | ID: mdl-34915058

RESUMEN

In response to rising rates of melanoma worldwide, novel noninvasive melanoma detection techniques are emerging to facilitate the early detection of melanoma and decrease unnecessary biopsies of benign pigmented lesions. Because they often report similar study findings, it may be difficult to determine how best to incorporate these technologies into clinical practice based on their supporting studies alone. The first article in this continuing medical education series provides practical advice on how and when to use various noninvasive melanoma detection techniques in clinical practice.


Asunto(s)
Melanoma , Neoplasias Cutáneas , Biopsia , Dermoscopía/métodos , Humanos , Melanoma/diagnóstico , Melanoma/patología , Microscopía Confocal/métodos , Sensibilidad y Especificidad , Neoplasias Cutáneas/diagnóstico , Neoplasias Cutáneas/patología
12.
Clin Dermatol ; 39(5): 757-761, 2021.
Artículo en Inglés | MEDLINE | ID: mdl-34785003

RESUMEN

Water has numerous functions necessary for survival including cellular homeostasis, solvent properties for dissolving ions and solutes, thermoregulation, and transport of waste and nutrients. Despite the established beneficial role of water in skin physiology, the optimal methods for skin hydration and requirements for daily water consumption remain elusive. This review summarizes the cellular and molecular biology of skin hydration, the debate and current recommendations of daily water requirements, and the latest research on interventions to improve skin hydration by both internal and external means of water exposure. We also explore the chemical properties of water, such as the concept of water "hardness" and environmental pollutants, and their impact on skin physiology.


Asunto(s)
Fenómenos Fisiológicos de la Piel , Agua , Humanos , Piel
13.
Clin Dermatol ; 39(5): 762-771, 2021.
Artículo en Inglés | MEDLINE | ID: mdl-34785004

RESUMEN

Cigarette and electronic cigarette use are significant public health concerns across the United States. Tobacco use remains the single most preventable cause of morbidity and mortality in the world. Electronic cigarettes initially emerged as a better alternative to conventional cigarettes and for promoting smoking cessation; however, current evidence reveals similar deleterious health implications caused by both products on almost all organ systems, including the skin. Recognition of the cutaneous manifestations associated with cigarette and electronic cigarette use is essential for dermatologists in current clinical practice. Dermatologists play a vital role in educating and counseling patients on smoking cessation. We specifically highlight the cutaneous consequences of conventional cigarette smoking and electronic cigarettes on dermatologic disease.


Asunto(s)
Sistemas Electrónicos de Liberación de Nicotina , Productos de Tabaco , Vapeo , Humanos , Nicotiana , Uso de Tabaco , Estados Unidos/epidemiología , Vapeo/efectos adversos
19.
J Am Acad Dermatol ; 85(1): 56-61, 2021 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-33610593

RESUMEN

BACKGROUND: Metformin has anticarcinogenic properties and is also known to inhibit the sonic hedgehog pathway, but population-based studies analyzing the potential protective effect for basal cell carcinoma (BCC) and squamous cell carcinoma (SCC) are needed. OBJECTIVES: To delineate the association between metformin use and invasive SCC, SCC in situ (SCCis), and BCC. METHODS: A population-based case-control study design was employed using all 6880 patients diagnosed in Iceland between 2003-2017 with first-time BCC, SCCis, or invasive SCC, and 69,620 population controls. Multivariate odds ratios (ORs) were calculated using conditional logistic regression. RESULTS: Metformin was associated with a lower risk of developing BCC (OR, 0.71; 95% confidence interval [CI], 0.61-0.83), even at low doses. No increased risk of developing SCC was observed. SCCis risk was mildly elevated in the 501-1500 daily dose unit category (OR, 1.40; 95% CI, 1.00-1.96). LIMITATIONS: This study was retrospective in nature with the inability to adjust for ultraviolet exposure, Fitzpatrick skin type, and comorbidities. CONCLUSION: Metformin is associated with decreased risk of BCC development, even at low doses. Metformin might have potential as a chemoprotective agent for patients at high risk of BCC, although this will need confirmation in future studies.


Asunto(s)
Carcinoma Basocelular/epidemiología , Metformina/uso terapéutico , Neoplasias Cutáneas/epidemiología , Anciano , Anciano de 80 o más Años , Carcinoma Basocelular/patología , Carcinoma Basocelular/prevención & control , Estudios de Casos y Controles , Femenino , Proteínas Hedgehog/antagonistas & inhibidores , Proteínas Hedgehog/metabolismo , Humanos , Islandia/epidemiología , Masculino , Metformina/farmacología , Persona de Mediana Edad , Estudios Retrospectivos , Factores de Riesgo , Transducción de Señal/efectos de los fármacos , Transducción de Señal/efectos de la radiación , Piel/efectos de los fármacos , Piel/patología , Piel/efectos de la radiación , Neoplasias Cutáneas/etiología , Neoplasias Cutáneas/patología , Neoplasias Cutáneas/prevención & control , Rayos Ultravioleta/efectos adversos
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...